Indian Pharmacopoeia Commission Flags ADR Linked To Meropenem

New Delhi: The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of May, has revealed that the carbapenem antibiotic Meropenem is linked with adverse drug reactions (ADRs) named Acute Generalized Exanthematous Pustulosis (AGEP).

In connection with the above, the Indian Pharmacopoeia Commission (IPC) has cautioned healthcare professionals to diligently monitor the potential occurrence of adverse drug reactions (ADRs) when administering Meropenem.

This came after a preliminary analysis of adverse drug reactions (ADRs) from the Pharmacovigilance Programme of India (PvPI) database.

Meropenem is a carbapenem antibiotic used to treat a wide variety of infections in the body. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell walls of most Gram-positive and Gram-negative bacteria to reach penicillin-binding protein (PBP) targets.

The alert noted that Meropenem is indicated for the treatment of pneumonia, nosocomial pneumonia, UTI, intraabdominal infection, gynaecological infection, skin and soft tissue infection, meningitis, septicaemia, and empiric treatment of presumed infection in adult patients with febrile neutropenia.

Following the preliminary analysis of adverse drug reactions (ADRs) from the PvPI database, it is reported that meropenem can lead to acute generalized exanthematous pustulosis (AGEP).

Acute generalized exanthematous pustulosis (AGEP) represents a severe, usually drug-related skin reaction characterized by acute formation of sterile pustules on an erythematous background, fever, and neutrophilia. AGEP is usually classified as a severe cutaneous adverse reaction (SCAR) to a prescribed drug. It is also called toxic pustuloderma.

Now, as per the issued drug safety alert, the following suspected drug is associated with the ADR as given below:

S. No Suspected Drug Indication Adverse Drug Reaction
1 Meropenem For the treatment of pneumonia, nosocomial pneumonia, UTI, intraabdominal infection, gynaecological infection, skin and soft tissue infection, meningitis, septicaemia, and empiric treatment of presumed infection in adult patients with febrile neutropenia. Acute Generalized Exanthematous Pustulosis (AGEP)

In light of the above, the Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, has advised healthcare professionals, patients, and consumers to closely monitor the possibility of the ADRs associated with the use of the above-suspected drugs.

Related Posts

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Fujifilm India, a leading healthcare technology company, has expanded its ELUXEO 8000 endoscopy portfolio with the launch of its next-generation therapeutic gastroscopes at Endocon 2026. India is witnessing a growing…

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Amidst years of uncertainty over the regulation of e-pharmacies in the country, the draft Drugs, Medical Devices and Cosmetics Bill, 2026, proposes to bestow the powers with the drugs inspectors…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?